Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01348789 · ClinicalTrials.gov registry record · NA
Safety for Frequent Use Conditions of Hair Removal Device
A NA study, sponsored by Syneron Medical.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT01348789: Completed NA study, sponsored by Syneron Medical.
NCT01348789 is a NA study that has completed, run by Syneron Medical. The registered enrollment target is 37 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01348789, a NA study, has completed, sponsored by Syneron Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
To measure the safety of hair removal device when used frequently.
Primary Outcome
The immediate skin reaction and long-term side and adverse effects were evaluated on site by a dermatologist. This includes the following clinical outcomes: * Presence of transient (disappearing \< 24 hours) or prolonged erythema * Presence of transient (disappearing \< 24 hours) or prolonged edema * Self-limited bleeding from mechanical shaving * Blister formation * Ulcer formation * Pigment changes (hypo/hyper) * Textural changes * Scarring * Infection * Pruritis * Post inflammation reactions
Interventions
- DEVICE Hair2Go (Mē)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-06 |
| Phase | NA |
What the finished NCT01348789 record still lists
NCT01348789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Hair2Go (Mē) is the first listed.
NCT01348789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01348789 about?
NCT01348789 is a clinical study titled "Safety for Frequent Use Conditions of Hair Removal Device". To measure the safety of hair removal device when used frequently.
What is the current status of trial NCT01348789?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2011-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01348789?
The interventions under investigation include: Hair2Go (Mē) (DEVICE).
Who is sponsoring clinical trial NCT01348789?
This trial is sponsored by Syneron Medical, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01348789's enrollment target sits among peer trials
37 1540th of 2000 higher than 460 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia